Dry eye treatment nearing approval

Article

ISTA Pharmaceuticals' dry eye candidate, ecabet sodium, has successfully completed Phase IIb testing and will soon be progressing to Phase III trials taking it a step closer to regulatory approval.

ISTA Pharmaceuticals' dry eye candidate, ecabet sodium, has successfully completed Phase IIb testing and will soon be progressing to Phase III trials, taking it a step closer to regulatory approval. Ecabet sodium combats dry eye by increasing mucin production.

Patients (n=144) were randomized to receive either ecabet sodium or placebo four times daily for 43 days. During the trial, patients treated with the compound demonstrated a strong trend towards improved results in terms of Tear Film Break-Up Time (TFBUT), tear production quantity and, to a lesser extent, Ocular Surface Disease Index (OSDI) symptoms. These objective and subjective positive trends were not observed in the placebo group. No systemic or ocular adverse events were noted in either treatment group. Patients displaying more severe symptoms of dry eye tended to respond better to ecabet sodium than to placebo.

ISTA Pharmaceuticals believes ecabet sodium improves both the quantity and quality of tears. ISTA is now considering four Phase III clinical trials to facilitate filing a New Drug Application (NDA) for this compound.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.